MDMA and temperature: A review of the thermal effects of 'Ecstasy' in humans

Drug and Alcohol Dependence

Volumn 121, Issue 1-2, 2012, Pages 1-9

  Parrott, A C ^a  

^a SWANSEA UNIVERSITY   (United Kingdom)

Author keywords

Dopamine; Ecstasy; Heat; Mdma; Neurotoxicity; Serotonin; Stress; Temperature; Thermal

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; SEROTONIN TRANSPORTER; UNCOUPLING PROTEIN;

BEHAVIORAL STRESS; BODY TEMPERATURE; CORE TEMPERATURE; ENVIRONMENTAL STRESS; ENVIRONMENTAL TEMPERATURE; HEAT STRESS; HOMEOSTASIS; HUMAN; HYPERPYREXIA; HYPERTHERMIA; MULTIPLE ORGAN FAILURE; NONHUMAN; PRIORITY JOURNAL; REVIEW; SKIN TEMPERATURE; SWEATING; THERMOGENESIS; THERMOREGULATION;

BODY TEMPERATURE; BODY TEMPERATURE REGULATION; DANCING; FEVER; HALLUCINOGENS; HUMANS; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE;

EID: 84855879694     PISSN: 03768716     EISSN: 18790046     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2011.08.012     Document Type: Review

References (66)

1. Banks M.L., Sprague J.E., Czoty P.W., Nader M.A. Effects of ambient temperature on the relative reinforcing strength of MDMA using a choice procedure in monkeys. Psychopharmacology 2008, 196:63-70.
2. Bedi G., Redman J. Recreational ecstasy use: acute effects potentiated by ambient conditions?. Neuropsychobiology 2006, 53:113.
3. Benemar K., Geller E.B., Adler M.W. A new brain area affected by 3,4-methylenedioxymethamphetamine: a microdialysis-biotelemetry study. Eur. J. Pharmacol. 2008, 596:84-88.
4. Brown P.L., Kiyatkin E.A. Brain hyperthermia induced by MDMA ('ecstasy'): modulation by environmental conditions. Eur. J. Neurosci. 2004, 20:51-58.
5. Brown C., Osterloh J. Multiple severe complications from recreational ingestion of MDMA ('Ecstasy'). JAMA 1987, 258:780-781.
6. Chadwick I.S., Curry P.D., Linsley A., Freemont A.J., Doran B. Ecstasy, 3,4-methylenedioxymethamphetamine (MDMA), a fatality associated with coagulopathy and hyperthermia. J. Royal Soc. Med. 1991, 84:371.
7. Cohen R.S. Subjective reports on the effects of the MDMA (Ecstasy) experience in humans. Prog. Neuropsychopharmacol. Biol. Psychiatry 1995, 19:1137-1145.
8. Cornish J.L., Schahnawaz Z., Thompson M.R., Wong S., Morley K.C., Hunt G.E., McGregor I.S. Heat increases 3,4-methylenedioxymethamphetamine administration and social effects in rats. Eur. J. Pharmacol. 2003, 482:339-341.
9. Corre J.R. A fatal trip with ecstasy: a case of 3,4-methylenedioxymethamphetamine toxicity. J. Royal Soc. Med. 1996, 89:51-52.
10. Dafters R. Hyperthermia following MDMA administration in rats: effects of ambient temperature, water consumption, and chronic dosing. Physiol. Behav. 1995, 58:877-882.
11. Davison D., Parrott A.C. Ecstasy in recreational users: self-reported psychological and physiological effects. Hum. Psychopharmacol. 1997, 12:91-97.
12. Farre M., Abanades S., Roset P.N., Peiro A.M., Torrens M., O'Mathuna B., Segura M., de la Torre R. Pharmacological interactions between 3,4-methylenedioxymethamphetamine (ecstasy) and paroxetine: pharmacological effects and pharmacodynamics. J. Pharmacol. Exp. Ther. 2007, 323:954-962.
13. Folkard S. Diurnal Variation. Stress and Fatigue in Human Performance 1983, Wiley, Chichester and New York.
14. Freedman R.R., Johanson C.E., Tancer M.E. Thermoregulatory effects of 3,4-methylenedioxymethamphetamine (MDMA) in humans. Psychopharmacology 2005, 183:248-256.
15. Gordon C.J. Thermophysiological response to hyperthermic drugs: extrapolating from rodent to human. Prog. Brain Res. 2007, 162:63-79.
16. Gordon C.J., Watkinson W.P., O'Callaghan J.P., Miller D.B. Effects of 3,4-methylenedioxymethamphetamine on thermoregulatory responses in the rat. Pharmacol. Biochem. Behav. 1991, 38:339-344.
17. Green A.R., Mechan A.O., Elliott J.M., O'Shea E., Colado M.I. The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy" ). Pharmacol. Rev. 2003, 55:463-508.
18. Green A.R., Sanchez V., O'Shea E., Saadat K.S., Elliott J.M., Colado M.I. Effect of ambient temperature and a prior neurotoxic dose of 3,4-methylenedioxymethamphetamine (MDMA) on the hyperthermic response of rats to a single or repeated ('binge' ingestion) low dose of MDMA. Psychopharmacology 2004, 173:264-269.
19. Greene S.L., Wood D.M., Dargan P.I. Epidemiological and clinical characteristics of acute MDMA related presentations to an inner city London Emergency Department. Neuropsychobiology 2009, 60:214.
20. Grob C.S., Poland R.E., Chang L., Ernst T. Psychobiologic effects of 3,4-methylenedioxymethamphetamine in humans: methodological considerations and preliminary observations. Behav. Brain. Res. 1996, 73:103-107.
21. Grunau B.E., Wiens M.O., Brubacher J.R. Dantrolene in the treatment of MDMA-related hyperpyrexia: a systematic review. CJEM 2010, 12:435-442.
22. Hall A.P., Henry J.A. Acute toxicity of 'Ecstasy' (MDMA) and related compounds: overview of pathophysiology and clinical management. Br. J. Anaesth. 2005, 96:678-685.
23. Halpern P., Moskovich J., Avrahami B., Bentur Y., Soffer D., Peleg K. Morbidity associated with MDMA (ecstasy) abuse-a survey of emergency department admissions. Hum. Exp. Toxicol. 2011, 30:259-266.
24. Harris D.S., Baggott M., Mendelson J.H., Mendelson J.E., Jones R.T. Subjective and hormonal effects of 3,4-methylenedioxymethamphetamine (MDMA) in humans. Psychopharmacology 2002, 162:396-405.
25. Henry J.A., Jeffries K.J., Dawling S. Toxicity and deaths from 3,4-methylenedioxymethamphetamine (" Ecstasy" ). Lancet 1992, 340:384-387.
26. Huether G., Zhou D., Ryuther E. Causes and consequences of the loss of serotonergic presynapses elicited by the consumption of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy" ) and its congeners. J. Neural Transm. 1997, 104:771-794.
27. Irvine R.J., Keane M., Felgate P., Mc Cann U.D., Callaghan P.D., White J.M. Plasma drug concentrations and physiological measures in dance party participants. Neuropsychopharmacology 2006, 31:424-430.
28. Kish S.J., Lerch J., Furukawa Y., Tong J., Mc Cluskey T., Wilkins D., Houle S., Meyer J., Mundo E., Wilson A.A., Rusjan P.M., Saint-Cyr J.A., Guttman M., Collins D.L., Shapiro C., Warsh J.J., Boileau I. Decreased cerebral cortical serotonin transporter binding in ecstasy users: a positron emission tomography/[(11)C]DASB and structural brain imaging study. Brain 2010, 133:1779-1797.
29. Kiyatkin E.A. Brian hyperthermia during physiological and pathological conditions: causes, mechanisms, and functional implications. Curr. Neurovasc. Res. 2004, 1:77-90.
30. Kolbrich E.A., Goodwin R.S., Gorelick D.A., Hayes R.J., Stein E.A., Huetis M.A. Physiological and subjective responses to 3,4-methylenedioxymethamphetamine administration. J. Clin. Psychopharmacol. 2008, 28:432-440.
31. Leon L.R. Thermoregulatory responses to environmental toxicants: the interactions of thermal stress and toxicant exposure. Toxicol. App. Pharmacol. 2008, 233:146-161.
32. Liechti M.E., Vollenweider F.X. The serotonin uptake inhibitor citalopram reduces cardiovascular and vegetative effects of 3,4-methylenedioxymethamphetamine (ecstasy) in human volunteers. J. Psychopharmacol. 2000, 14:269-274.
33. 2 antagonist ketanserin in healthy humans. Neuropsychopharmacology 2000, 23:396-404.
34. Liechti M.E., Gamma A., Vollenweider F.X. Gender differences in the subjective effects of MDMA. Psychopharmacology 2001, 154:161-168.
35. Malberg J.E., Seiden L.S. Small changes in ambient temperature cause large changes in 3,4-methylenedioxymethamphetamine (MDMA)-induced serotonin neurotoxicity and core body temperature in the rat. J. Neurosci. 1998, 18:5086-5094.
36. Mas M., Farre M., de la Torre R., Roset P.N., Ortuno J., Segura J., Cami J. Cardiovascular and neuroendocrine effects and pharmacokinetics of 3,4-methylenedioxymethamphetamine in humans. J. Pharmacol. Exp. Ther. 1999, 290:136-145.
37. Mills E.M., Rusyniak D.E., Sprague J.E. The role of the sympathetic nervous system and uncoupling proteins in the thermogenesis induced by 3,4-methylenedioxymethamphetamine. J. Mol. Med. 2004, 82:787-799.
38. Morefield K.M., Keane M., Felgate P., White J.M., Irvine R.J. The acute psychobiological impacts of ilicit 3,4-methylenedioxymethamphetamine (MDMA, 'Ecstasy') consumption in recreational environments. Neuropsychobiology 2009, 60:216.
39. Morris D. The Naked Ape 1967, Corgi Press, London.
40. Olausson H., Charron J., Marchand S., Villemure C., Strigo I.A., Bushnell M.C. Feelings of warmth correlate with neural activity in right anterior insular cortex. Neurosci. Lett. 2005, 389:1-5.
41. Parrott A.C. Human psychopharmacology of ecstasy (MDMA): a review of fifteen years of empirical research. Hum. Psychopharmacol. 2001, 16:557-577.
42. Parrott A.C. Recreational ecstasy/MDMA, the serotonin syndrome, and serotonergic neurotoxicity. Pharmacol. Biochem. Behav. 2002, 71:837-844.
43. Parrott A.C. Is ecstasy MDMA? A review of the proportion of ecstasy tablets containing MDMA, dosage levels, and the changing perceptions of purity. Psychopharmacology 2004, 173:234-241.
44. Parrott A.C. MDMA (3,4-methylenedioxymethamphetamine) or Ecstasy: the neuropsychobiological implications of taking it at dances and raves. Neuropsychobiology 2004, 50:329-335.
45. Parrott A.C. Chronic tolerance to recreational MDMA (3,4-methylenedioxymethamphetamine) or Ecstasy. J. Psychopharmacol. 2005, 19:71-83.
46. Parrott A.C. MDMA in humans: factors which affect the neuropsychobiological profiles of recreational Ecstasy users, the integrative role of bio-energetic stress. J. Psychopharmacol. 2006, 20:147-163.
47. Parrott A.C. Cortisol and MDMA (3,4-methylenedioxymethamphetamine): neurohormonal aspects of bioenergetic-stress in Ecstasy users. Neuropsychobiology 2009, 60:148-158.
48. Parrott A.C., Young L. Increased body temperature in recreational Ecstasy/MDMA users out clubbing and dancing. J. Psychopharmacol. 2005, 19:a26.
49. Parrott A.C., Rodgers J., Buchanan T., Ling J., Heffernan T., Scholey A.B. Dancing hot on ecstasy: physical activity and thermal comfort ratings are associated with the memory and other psychobiological problems of recreational MDMA users. Hum. Psychopharmacol. 2006, 21:285-298.
50. Parrott A.C., Milani R.M., Gouzoulis-Mayfrank E., Daumann J. Cannabis and Ecstasy/MDMA (3,4-methylenedioxymethamphetamine): an analysis of their neuropsychobiological interactions in recreational users. J. Neural Transm. 2007, 114:959-968.
51. Parrott A.C., Adnum L., Evans A., Kissling C., Thome J. Heavy Ecstasy/MDMA use at cool house parties: substantial cortisol release and increased body temperature. J. Psychopharmacol. 2007, 21:a35.
52. Parrott A.C., Lock J., Conner A.C., Kissling C., Thome J. Dance clubbing on MDMA and during abstinence from Ecstasy/MDMA: prospective neuroendocrine and psychobiological changes. Neuropsychobiology 2008, 57:165-180.
53. Patel M.M., Belson M.G., Longwater A.B., Olson K.R., Miller M.A. Methylenedioxymethamphetamine (ecstasy)-related hyperthermia. J. Emerg. Med. 2005, 29:451-454.
54. Peroutka S.J., Newman H., Harris H. Subjective effects of 3,4-methylenedioxymethamphetamine in recreational users. Neuropsychopharmacology 1988, 1:273-277.
55. Rusniak D.E., Sprague J.E. Toxin-induced hyperthermic syndromes. Med. Clin. North Am. 2005, 89:1277-1296.
56. Schifano F., Corkery J., Deluca P., Oyefeso A., Ghodse A.H. Ecstasy (MDMA, MDA, MDEA, MBDB) consumption, seizures, related offences, prices, dosage levels and deaths in the UK (1994-2003). J. Psychopharmacol. 2006, 20:456-463.
57. Shulgin A.T. The background and chemistry of MDMA. J. Psychoactive Drugs 1986, 18:291-304.
58. Sprague J.E., Mallett N.M., Rusniak D.E., Mills E. Hypothalamic-pituitary-thyroid axis and sympathetic nervous system involvement in hyperthermia induced by 3,4-methylenedioxymethamphetamine (Ecstasy). J. Pharmacol. Exp. Ther. 2003, 305:159-166.
59. Sprague J.E., Yang X., Sommers J., Gilman T.L., Mills E.M. Roles of norepinephrine, free fatty acids, thyroid status, and skeletal muscle uncoupling protein 3 expression in sympathomimetic-induced thermogenesis. J. Pharmacol. Exp. Ther. 2007, 320:274-280.
60. Suy K., Gijsenbergh F., Baute L. Emergency medical assistance during a mass gathering. Eur. J. Emerg. Med. 1999, 6:249-254.
61. Tancer M.E., Johanson C.E., Freedman R.R. MDMA elevates core temperature in warm and cold conditions in man. College on Problems of Drug Dependence Annual Conference 2003, Conference Abstract, p. 169.
62. Topp L., Hando J., Dillon P., Roche A., Solowij N. Ecstasy use in Australia: patterns of use and associated harm. Drug Alcohol Depend. 1999, 55:105-115.
63. Vollenweider F.X., Gamma A., Liechti M., Huber T. Psychological and cardiovascular effects and short-term sequelae of MDMA (" ecstasy" ) in MDMA-naive healthy volunteers. Neuropsychopharmacology 1998, 19:241-251.
64. White S.R. Amphetamine toxicity. Semin. Respir. Crit. Care Med. 2002, 23:27-36.
65. Williams H., Dratcu L., Taylor R., Roberts M., Oyefeso A. Saturday night fever: ecstasy related problems in a London accident and emergency department. J. Acc. Emerg. Med. 1998, 15:322-326.
66. Winstock A.R., Griffiths P., Stewart D. Drugs and the dance music scene: a survey of current drug use patterns among a sample of dance music enthusiasts in the UK. Drug Alcohol Depend. 2001, 64:9-17.